

TorreyPines Therapeutics, Inc.  
Form 8-K  
March 27, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**  
**FORM 8-K**  
**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 27, 2009

**TORREYPINES THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction

**000-25571**  
(Commission

**86-0883978**  
(IRS Employer

of Incorporation)

File Number)

Identification No.)

**11085 North Torrey Pines Road, Suite 300, La Jolla, CA**  
(Address of Principal Executive Offices)

**92037**  
(Zip Code)

Registrant's telephone number, including area code: (858) 623-5665

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

.. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

## Edgar Filing: TorreyPines Therapeutics, Inc. - Form 8-K

- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition.**

On March 27, 2009 TorreyPines Therapeutics, Inc. (the Company ) announced its financial results for the quarter and year ended December 31, 2008 in the earnings release furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information in this Item 2.02 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act.

**Item 8.01. Other Events.**

In compliance with Nasdaq Marketplace Rule 4350(b)(1)(B), the Company s earnings release furnished as Exhibit 99.1 to this Current Report on Form 8-K announced that the report on its financial statements for the year ended December 31, 2008 contains an audit opinion with a going concern explanatory paragraph.

**Item 9.01. Results of Operations and Financial Condition.**

(d) The following exhibit is furnished herewith:

99.1 Press release dated March 27, 2009.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TORREYPINES THERAPEUTICS, INC.

Date: March 27, 2009

By: /s/ Craig Johnson

Name: Craig Johnson

Title: Vice President, Finance and Chief Financial Officer

**INDEX TO EXHIBITS**

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Press release dated March 27, 2009